Clinical Trials
43 trialsPrevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
APHYPAP
University Hospital, Brest
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
The First Affiliated Hospital of Zhengzhou University
NRR
UNC Lineberger Comprehensive Cancer Center
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
Spanish Breast Cancer Research Group
CINV
Sun Yat-sen University
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Fudan University
Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
University Health Network, Toronto
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
EGFR-TKIs
Sun Yat-sen University
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Barbara Ann Karmanos Cancer Institute
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
Shiga University
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
ChineseAMS
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Hunan Province Tumor Hospital
KMEC
Merck Sharp & Dohme LLC
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
RAPA
Kangdong Sacred Heart Hospital
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Gynecologic Oncology Associates
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Hoosier Cancer Research Network
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
Pfizer
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Washington University School of Medicine
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Samsung Medical Center
AprepIt
Campus Bio-Medico University
ONO-7436 Phase II Study in Japan
Ono Pharmaceutical Co., Ltd.
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
AMENO-2
PETHEMA Foundation